Immunogenicity of a recombinant DNA hepatitis B vaccine in neonates.
Infants of HBsAg-positive mothers (Group I) as well as those born to women without HBV markers (Group II) were vaccinated with a 10 micrograms dose of a recombinant DNA hepatitis B vaccine within 24 hours after birth according to a 0, 1, and 2 month schedule, with a booster dose planned 12 months later. Vaccination results in 14 (Group I) and 47 (Group II) neonates showed that at two months after the third dose of vaccine, 86% (6/7) and 100% (37/37), respectively, seroconverted, with anti-HBs geometric mean titres of 80 IU/l and 266 IU/l in the respective groups. No adverse reactions to the vaccine were observed. These preliminary results indicate that the recombinant DNA hepatitis B vaccine is safe and highly immunogenic in newborns.
Meheus
A
A
Department of Epidemiology, University of Antwerp, Belgium.
Alisjahbana
A
A
Vranckx
R
R
Sukadi
A
A
Usman
A
A
Ngantung
W
W
Sugita
E
E
Safary
A
A
André
F
F
Reniers
J
J
D000941:Antigens / Q000627:therapeutic use*; D004274:DNA, Recombinant / Q000276:immunology; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis*; D006801:Humans; D007231:Infant, Newborn; D012441:Saccharomyces cerevisiae / Q000235:genetics; D013997:Time Factors; D014611:Vaccination / Q000009:adverse effects; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*
D000941:Antigens; D004274:DNA, Recombinant; D006510:Hepatitis B Antibodies; D014614:Vaccines, Synthetic